Abstract
One of the most important changes in the treatment of patients with diabetes mellitus type 2 with oral agents are "New guidelines for DM type 2", which were prepared of IDF, EASD and ADA. Treatment strategy is changing with emphasis on the early starting of farmacological treatment with metformin as an agent of "first choice".
Besides 5?groups of oral agents we have at present 6. group - gliptines, a representative of a new incretin strategy of treatment type 2 diabetes mellitus. We require besides a hypoglycemic effect of oral agents also other their abilities: longacting and permanent effect, not increasing body weight, minimal side effects and positive influence on cardiovascular risk.